Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 ______________________________________________ FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _______________________________________________________ For the fiscal year ended December 31, 2023 Commission file number 1-2189 Abbott Laboratories An Illinois Corporatio ...

Abbott Laboratories ABT, -1.06% said that a Food and Drug Administration panel voted in favor of the safety profile of its heart device TriClip. The medical device company on Tuesday said that the Circulatory System Devices Panel of the Medical Devices Advisory Committee also confirmed the effectiveness and risk/benefit profile of the device to treat people with tricuspid regurgitation. Tricuspid regurgitation is a type of heart valve disease that occurs when the tricuspid valve doesn’t close tight enoug ...

Panel of independent experts reviewed data from the TRILUMINATE™ pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system An investigational device in the U.S., TriClip is approved in more than 50 countries and has treated more than 10,000 people with tricuspid regurgitation worldwide ABBOTT PARK, Ill., Feb. 13, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the U.S. ...

One of the biggest themes in the healthcare industry right now is the rise of effective new obesity and diabetes medications. Novo Nordisk and Eli Lilly are dominating the space with blockbuster drugs including Ozempic, Rybelsus, Wegovy, Mounjaro, and Zepbound.As demand for these glucagon-like peptide-1 (GLP-1) agonists continues to surge, other pharmaceutical companies, including Hims & Hers Health and start-up Ro, are looking to make inroads with their own versions.But savvy investors understand that othe ...

The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities in 2024. The sector is valuable because it has stayed flexible and grown along with improvements in medical tools, treatment methods, and healthcare services all around the world.This rapid rise sparked companies in the sector. It was also expected to raise living standards by offering new medical solutions. So, when we b ...

Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this maker of infant formula, medical devices and drugs have returned -0.9%, compared to the Zacks S&P 500 composite's +5.1% change. During this period, the Zacks Medical - Products industry, which Abbott falls in, has gained 2.6%. The key question now is: What could be the ...

One mistake investors make when buying dividend stocks is chasing yield. Stocks with the highest yield could be a sign a company is struggling, which could put the yield at risk. Particularly in high-interest-rate environments such as we’re in today, a company might have difficulty maintaining its payout.Wellington Management looked at dividend stocks over 92 years between 1930 and 2022. It found stocks offering the highest level of payouts didn’t perform as well as those paying high, but not the very highe ...

Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Abbott (ABT) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Styl ...

When is it time to buy a stock? One of the best-known pieces of investing advice tells us to buy low and sell high. But what constitutes "low" is relative. A stock near its 52-week high can still be considered at a "low" point, provided there's plenty of upside left. That's why investors shouldn't ignore such stocks.With that as a backdrop, let's look at two companies trading near their 52-week highs and are still worth buying: Abbott Laboratories (ABT 0.20%) and Netflix (NFLX 1.04%).1. Abbott LaboratoriesA ...

Drugmakers Novo Nordisk and Eli Lilly have been making headlines in recent times, thanks to their sought-after weight loss drugs. In fact, the products have become so popular that demand has surpassed supply -- and the companies have been ramping up production to try to keep up.Novo Nordisk's Ozempic and Eli Lilly's Mounjaro are approved for type 2 diabetes, but doctors also have prescribed them for weight loss. And the companies sell the same molecules specifically approved for weight loss under different ...